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Abstract This paper studies the cytotoxic effect induced by the
topoisomerase I inhibitor camptothecin in human osteosarcoma
Saos-2 cells, which lack p53 and contain a non-functional form of
the product of the retinoblastoma gene, pRb. Cytotoxicity
induced by camptothecin was dose- and time-dependent; the
treatment with 100 nM camptothecin reduced cell viability by
50% at 32 h and by 75% at 72 h of exposure. The cytotoxic effect
was caused by apoptosis, as ascertained by morphological
evidence, acridine orange-ethidium bromide staining and flow
cytometric analysis. Apoptosis was accompanied by both the
activation of caspase-3 and the fragmentation of poly(ADP-
ribose) polymerase. Treatment with camptothecin caused a
threefold increase in the activity of c-Jun N-terminal kinase
(JNK) and an eightfold increase in the level of phosphorylated
c-Jun. The introduction of the RB gene into Saos-2 cells reduced
the rate of cell growth. Moreover, stable clones of transfected
cells were resistant to camptothecin. Exposure to 100 nM
camptothecin for 72 h reduced the viability of transfected cells by
only 10%; moreover, very modest effects were observed on the
activity of JNK as well as on the level of phosphorylated c-Jun.
The results reported in this paper support the conclusion that the
expression of wild-type pRb in Saos-2 cells exerts an anti-
apoptotic influence through the control of JNK activity. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
The product of the retinoblastoma gene, pRb, plays a role
in regulating the progression of proliferating cells through the
cell cycle [1]. pRb behaves as a transcriptional repressor by
binding to the transactivation domain of E2F and inhibiting
its transcriptional activity, which is required for the progres-
sion of cells from G1 into S phase [1]. In recent years, much
evidence has suggested that pRb is also involved in the termi-
nal di¡erentiation of many tissues, by inducing cell cycle exit
and by potentiating the activity of tissue-speci¢c transcription
factors [2]. For example, pRb positively regulates the activity
of MyoD and C/EBP, two transcription factors required for
the expression of genes involved in the di¡erentiation of re-
spectively muscle and fat cells [3,4].
Apart from these roles in the control of the cell cycle and
di¡erentiation, an anti-apoptotic role has been suggested for
pRb in a series of recent papers which correlate the loss of
pRb with the induction of apoptosis. The appearance of ap-
optosis in speci¢c neuronal compartments and in the develop-
ing lens has been observed in Rb3/3 mouse embryos and
these results have been interpreted as a response to the loss
of pRb [5]. Moreover, the cleavage of pRb by caspase activ-
ities has been considered to be an early permissive step in the
apoptosis-inducing pathway [6]. Apoptosis in pRb-defective
cells can be induced by the wild-type form of p53 [7]. Accu-
mulation of p53 can be promoted by E2F, a transcriptional
factor which is in a free state when pRb is absent in the cells.
Free E2F stimulates the expression of p19ARF which binds
MDM2, thus inhibiting MDM2-mediated degradation of
p53 and favoring the accumulation of p53 [8]. However, other
apoptotic pathways independent of p53 activity have been
described in di¡erent circumstances by many authors [9].
Evidence has been provided for a role in the initiation of
apoptosis for c-Jun N-terminal kinase (JNK/SAPK), a mem-
ber of mitogen-activated protein (MAP) kinase which can be
activated by either oxidative stress or in£ammatory cytokines
[10,11]. Even DNA-damaging agents such as topoisomerase
inhibitors or Q radiation have been demonstrated to activate
the stress signalling pathway of JNK, with the consequent
increase in the phosphorylation of c-Jun [12,13].
The present study was carried out to assess the potential
apoptotic e¡ect of both camptothecin and its analogue top-
otecan in human osteosarcoma Saos-2 cells, which are defec-
tive in both pRb and p53. Our results indicate that campto-
thecin induces a clear apoptotic e¡ect in Saos-2 cells, which is
independent of oxidative stress and correlates with the activa-
tion of JNK. Our results support the conclusion that the in-
troduction of pRb into Saos-2 cells exerts an anti-apoptotic
e¡ect by inhibiting the activity of JNK.
2. Materials and methods
2.1. Cell cultures and reagents
Human osteosarcoma Saos-2 cells (obtained from the German Col-
lection of Microorganisms and Cell Cultures, Braunschweig, Ger-
many) were grown as monolayers in McCoy’s 5A medium, supple-
mented with 10% heat-inactivated fetal calf serum at 37‡C in a
humidi¢ed atmosphere containing 5% CO2.
Unless stated otherwise, incubations were performed with cells
seeded on 96-well plates (7U103 cells) or 100-mm tissue culture dishes
(1U106 cells). After plating, cells were allowed to adhere overnight
and then treated with chemicals or vehicle (control cells) as described
in the legends of ¢gures and in the text.
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Cell viability was determined by either a MTT colorimetric assay
[14] or a standard trypan blue dye exclusion assay.
Morphological analysis of apoptosis was performed by acridine
orange-ethidium bromide (AO/EB) staining, using monolayer cultures
in 96-well plates. After removal of the medium, cells were rinsed and
treated with a solution of 100 Wg/ml AO and 100 Wg/ml EB. The
di¡erence in the uptake of these two dyes allowed the identi¢cation
of viable and non-viable cells by £uorescence microscopy. Viable cells
display normal nuclei with a homogeneous chromatin staining pattern
and bright green £uorescence whereas dead apoptotic cells show typ-
ical condensed and fragmented chromatin with bright orange £uores-
cence. Dead necrotic cells display a di¡use orange staining pattern.
z-VAD-fmk (benzyloxycarbonyl-Val-Ala-Asp-£uoromethylketone)
was obtained from Bachem AG (Bubendorf, Switzerland). Other
chemicals, except where stated otherwise, were obtained from Sigma
(St. Louis, MO, USA). Stock solutions of topoisomerase inhibitors
were prepared in dimethyl sulfoxide (DMSO) and diluted to their ¢nal
concentrations in the culture medium. The ¢nal concentration of
DMSO never exceeded 0.04%, a concentration which had no discern-
ible e¡ect on Saos-2 cells in comparison with the control.
2.2. Transfection of Saos-2 cells with the RB gene
Saos-2 cells were seeded on 6-well plates (1U105 cells/well) in 2 ml
McCoy’s medium, and transfected using FuGene transfection reagent
(Boehringer Mannheim, Darmstadt, Germany) following the standard
manufacturer’s protocol. The vector used was p-CMV-Rb1-puro plas-
mid (1.5 Wg DNA/well) (provided by Dr. M. Crescenzi, Regina Elena
Cancer Institute, Rome, Italy), containing full-length RB cDNA and
the puromycin resistance gene. After incubation for 48 h with FuGene
reagent, resistant clones were selected for 4 weeks with puromycin
(1 Wg/ml) and then expanded into cell lines in medium containing
0.1 Wg/ml puromycin. The three clones that showed the highest ex-
pression of pRb by means of Western blotting analysis were used for
further experiments. The ¢gures show the results obtained with clone
C25.
2.3. Cell cycle analysis
The distribution of cells in the cell cycle phases was determined as
previously reported [15]. Saos-2 cells were washed twice in cold phos-
phate-bu¡ered saline (PBS) and stained with a hypotonic £uoro-
chrome solution containing 50 Wg/ml propidium iodide. Flow cyto-
metric analysis of stained nuclei was performed in a FACSort
instrument (Becton Dickinson) and £uorescence was analyzed as a
single-parameter frequency histogram. Data were analyzed using
MedFit TL software (Becton Dickinson).
2.4. Detection of intracellular H2O2
Production of H2O2 was quanti¢ed by a microassay modi¢cation of
the red phenol method [16]. Saos-2 cells, seeded in 24-well plates
(5U104 cells/well), were covered with 150 Wl/well of assay solution
(0.02% red phenol in red phenol-free BSS containing 6 U/ml horse-
radish peroxidase, type II) and incubated for 1 h at 37‡C in 95% air^
5% CO2. Then 15 Wl of 1 N NaOH was added to each well. The
amount of oxidized red phenol was measured by an automatic micro-
plate enzyme immunoassay photometer (Opsys MR; Dynex Technol-
ogies) at 630 nm wavelength. Mean absorbance values from 10 repli-
cate wells were calculated and the results are expressed as nmol H2O2
produced per 106 cells.
In other experiments, intracellular peroxide levels were assessed
using 2P,7P-dichlorodihydro£uorescein diacetate (DCFDA, Molecular
Probes, Leiden, The Netherlands). DCFDA (5 WM) was added to cell
cultures during the last hour of treatment. Then, the dye was removed
and the cells were washed twice with PBS, trypsinized and ¢nally
resuspended in 5 ml of PBS. Cells were analyzed using a £ow cytom-
eter (Becton Dickinson).
2.5. Reduced glutathione (GSH) content assay
Glutathione levels were determined using a glutathione colorimetric
assay kit (Calbiochem-Novabiochem Corporation, San Diego, CA,
USA). For this assay, Saos-2 cells (2U106) were cultured in 100-
mm petri plates and treated for 48 h with 100 nM camptothecin in
the conditions reported in Section 3.
2.6. JNK assay
SAPK/JNK activity was measured using a non-radioactive method
(New England Biolabs, Hitchin, UK). Cells were lysed as reported in
the manufacturer’s instructions, sonicated in a Soniprep 150 appara-
tus (MSE) (four times for 5 s) and centrifuged (14 000 rpm) for 10 min.
JNK activity was precipitated from whole cell lysates (250 Wg of
protein) with 2 Wg of GST-c-Jun fusion protein/GSH-Sepharose beads
overnight at 4‡C. The beads were washed twice in lysis bu¡er, resus-
pended in 50 Wl kinase bu¡er supplemented with 100 mM ATP and
incubated for 30 min at 30‡C. To evaluate the phosphorylation of
GST-c-Jun on Ser63 equivalent amounts of protein were resolved
by SDS^PAGE, electrotransferred to nitrocellulose and detected
with a speci¢c anti-phospho-c-Jun antibody. Bands were quanti¢ed
by densitometric analysis.
2.7. Western blot analysis
Cells were lysed for 30 min at 4‡C with a solution (15 Wl/106 cells)
composed of 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS in PBS
(pH 7.4), containing inhibitors of proteases. Cells were then sonicated
three times for 10 s and centrifuged at 15 000Ug for 20 min at 4‡C.
Equivalent amounts of proteins (60 Wg) were resolved by SDS^PAGE
and electrotransferred to nitrocellulose for detection with speci¢c anti-
bodies. All antibodies employed were purchased by Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Visualization was performed us-
ing nitroblue tetrazolium and bromochloro-indoyl-phosphate. Finally,
bands were quanti¢ed by densitometric analysis.
3. Results
3.1. Topoisomerase inhibitors reduce the viability of human
osteosarcoma Saos-2 cells
We evaluated the e¡ect of camptothecin, an inhibitor of
topoisomerase I, on the viability of human osteosarcoma
Fig. 1. Time course of the inhibitory e¡ect induced on the viability of Saos-2 cells by camptothecin. Parental (A) or RB-transfected (B) Saos-2
cells were treated with di¡erent doses of camptothecin for 0, 16, 24, 32, 48 and 72 h. The number of viable cells was then determined using the
MTT colorimetric assay and is expressed as a percentage of untreated cells. Data are the means of four separate experiments, each in triplicate.
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Saos-2 cells, as measured by the MTT assay. As shown in Fig.
1A, treatment with camptothecin reduced Saos-2 cell viability
in a dose- and time-dependent manner. With 100 nM, cell
viability progressively decreased after a lag phase of 16 h,
reaching 50% of the control value at 32 h and 25% at 72 h
of treatment.
A similar e¡ect was obtained when the cells were treated
with topotecan, an analogue of camptothecin used in cancer
chemotherapy. Treatment with 100 nM topotecan reduced the
viability of Saos-2 cells to 56% at 32 h and 30% at 72 h of
treatment (not shown).
The inhibitors of topoisomerase II were less e⁄cacious than
camptothecin. The treatment with 1 WM etoposide reduced
Saos-2 cell viability by only 10% at 32 h and 32% at 72 h
of treatment (not shown).
3.2. The reduction of Saos-2 cell viability is caused by apoptotic
cell death
Light microscopy demonstrated that Saos-2 cells treated
with camptothecin detached themselves from the substrate
and assumed a round shape (Fig. 2A). Analysis by £uores-
cence microscopy after staining with AO/EB permitted us to
establish that camptothecin induces apoptosis in Saos-2 cells.
The frequency of apoptotic cells was measured in samples
treated with 100 nM camptothecin for 24 and 48 h. Compar-
ison between the frequency of apoptotic cells and that of total
dead cells (Table 1) strongly suggests that the loss of viability
was primarily due to apoptosis.
The rate of apoptosis was also estimated by £ow cytometry.
As shown in Fig. 2B, the treatment with 100 nM camptothe-
cin enhanced the subdiploid G0/G1 population which, after
48 h of exposure, reached 63.5% of the total cells. This value
was in agreement with the percentage of non-viable cells eval-
uated by either AO/EB analysis or MTT assay.
Western blotting analysis was used to examine the activa-
tion of caspase-3, a protease involved in apoptotic pathways
[17]. As shown in Fig. 3, the treatment with 100 nM campto-
thecin for 48 h induced fragmentation of procaspase-3, with
the production of the active form of caspase-3. The same
treatment with 100 nM camptothecin also induced the frag-
mentation of poly(ADP-ribose) polymerase (PARP), with the
appearance of an 85-kDa apoptotic fragment (Fig. 3). More-
over, the addition of z-VAD, a general inhibitor of caspase
activities, completely suppressed the e¡ect of camptothecin on
cell viability (not shown) and on PARP degradation, indicat-
ing the involvement of caspases in camptothecin-mediated ap-
optosis.
In some experiments we treated Saos-2 cells with combina-
tions of camptothecin and MG132, a good inducer of apopto-
sis, and we observed that combined treatments gave additive
e¡ects on cell viability. For example, the viability of Saos-2
cells was reduced by 48% and 55% when the cells were sepa-
rately treated with 0.5 WM MG132 and 50 nM camptothecin
respectively, while combined treatment lowered the viability
by 75% (not shown).
3.3. Oxidative stress is not involved in the apoptotic process
induced by camptothecin
To ascertain the potential role of oxidative damage in
camptothecin-induced toxicity, we studied the e¡ect of 100
nM camptothecin on the cellular level of hydrogen peroxide.
Fig. 2. Morphological (A) and £ow cytometric (B) analysis of Saos-
2 cells after treatment with camptothecin. Saos-2 cells were cultured
for 48 h in the absence or presence of 100 nM camptothecin. Cells
were then examined using conventional light microscopy and photo-
graphed (A). Flow cytometric analysis, shown in B, was performed
by DNA staining with propidium iodide as reported in Section 2.
The vertical axis represents the relative number of events and the
horizontal axis the £uorescence intensity. The percentages indicate
the subdiploid population of cells.
Table 1
The loss of viability and the induction of apoptosis in Saos-2 cells treated with camptothecin
Dead cells (%) Apoptotic cells (%)
hours of treatment hours of treatment
24 48 24 48
Parental cells Control cells 2.1 þ 0.2 7.1 þ 0.7 2.2 þ 0.3 4.1 þ 0.3
Camptothecin 32.2 þ 2.8 69.8 þ 7.1 29.3 þ 3.1 64.2 þ 6.4
+z-VAD 4.9 þ 0.4 15 þ 1.6 5 þ 0.5 10 þ 1.1
Transfected cells Control cells 1.5 þ 0.1 2.1 þ 0.2 1.4 þ 0.1 1.9 þ 0.2
Camptothecin 3.1 þ 0.3 10.0 þ 0.9 2.5 þ 0.2 8.1 þ 0.7
+z-VAD 3.2 þ 0.3 9.2 þ 0.9 2.1 þ 0.2 7.2 þ 0.6
Parental and RB-transfected cells were cultured for 24 and 48 h in the absence or presence of 100 nM camptothecin. 100 WM zVAD was added
when reported. Cells were stained with trypan blue or AO/EB and the frequency of non-viable cells compared to that of apoptotic cells.
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During a period of time between 0.5 and 48 h of treatment
only modest increases in H2O2 level (+10^15%) were found
using the red phenol procedure (Fig. 4A). Data were con-
¢rmed by means of cyto£uorimetric analysis using DCFDA
as a £uoroprobe.
We also evaluated the content of GSH in cells treated for
48 h with 100 nM camptothecin. Data shown in Fig. 4B in-
dicate that camptothecin induced only a modest decrease in
the intracellular content of GSH. Moreover, the addition of
GSH (400 Wg/ml) (Fig. 4C) or N-acetylcysteine (20 mM) (not
shown) to the cultures treated with camptothecin only mod-
estly reduced the apoptotic e¡ect caused by the drug. In line
with these results, the addition of BSO, a potent speci¢c in-
hibitor of Q-glutamylcysteine synthetase (the rate-limiting step
in glutathione biosynthesis), was unable to increase the e¡ect
of camptothecin (not shown).
Finally, the addition of exogenous catalase (1 mg/ml), an
e¡ective cellular H2O2-decomposing enzyme, did not modify
the apoptotic e¡ect exerted by camptothecin (not shown).
3.4. The apoptotic e¡ect of camptothecin is mediated by JNK
activation
As it is well known that some DNA-damaging drugs acti-
vate JNK [18,19], we evaluated whether the JNK signalling
pathway is functionally involved in camptothecin-induced ap-
optosis. JNK activity was tested using a procedure which
employs the N-terminal c-Jun fusion protein. As shown in
Fig. 5A, the level of JNK activity was very low in untreated
Saos-2 cells. This level was enhanced with camptothecin treat-
ment, reaching a threefold increase after 48 h exposure to 100
nM (Fig. 5C). As a consequence of JNK activation, the level
of phosphorylated c-Jun was also markedly enhanced after
48 h of treatment, reaching a level of about eight times the
control value (Fig. 5C). This e¡ect was not modi¢ed by the
addition of 100 WM z-VAD, indicating that caspase proteases
are not involved in the activation of JNK (Fig. 5B). Similar
e¡ects on JNK activity and on phosphorylation of c-Jun were
also observed on treating the cells for 48 h with 100 nM top-
otecan (not shown).
Using Western blotting analysis we evaluated the cellular
levels of a number of apoptosis modulators such as Bcl-2,
Bax, p21 and E2F. It was observed that treatment with 100
nM camptothecin did not signi¢cantly modify the levels of
these proteins (not shown).
3.5. Transfection of Saos-2 cells with the RB gene reduced the
e¡ect exerted by camptothecin on both apoptosis and JNK
activation
To evaluate the role of pRb in camptothecin-induced apo-
ptosis, the wild-type RB gene was introduced by transfection
into Saos-2 cells, and clones of transfected cells expressing
Fig. 3. Western blotting analysis of caspase-3 and PARP in Saos-2
cells. Saos-2 cells were treated for 48 h with 100 nM camptothecin
in the absence or presence of 100 WM z-VAD. Cell lysates were pre-
pared as reported in Section 2, resolved by 10% SDS^PAGE, immu-
noblotted and detected using speci¢c antibodies.
Fig. 4. Detection of hydrogen peroxide (A) and GSH (B) in Saos-2
cells treated with camptothecin. The in£uence of exogenous GSH
on the cytotoxic e¡ect exerted by camptothecin (C). Saos-2 cells
were treated for various times with camptothecin with or without
GSH, as indicated in the ¢gure. The number of viable cells was as-
sessed using the MTT procedure and is expressed as a percentage of
untreated cells. H2O2 was evaluated by means of the red phenol
method and GSH content by means of a colorimetric assay as re-
ported in Section 2. Data are the means of four separate experi-
ments, each in triplicate.
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wild-type pRb were selected and expanded into cell lines. The
presence of pRb in transfected cells was analyzed by means of
Western blotting analysis using a monoclonal antibody that
recognizes the central portion of pRb. As shown in Fig. 6,
only a 95-kDa band, related to a truncated form of pRb, was
detected in parental Saos-2 cell line, while in transfected Saos-
2 cells the presence of the normal-size Rb protein (105 kDa)
was ascertained in addition to the 95-kDa truncated form. All
transfected clones exhibited a slower rate of cell growth com-
pared to parental Saos-2 cells. Moreover, RB-transfected cells
appeared enlarged and £attened with many dendritic-like pro-
trusions (not shown).
RB-transfected clones exhibited clear resistance to the e¡ect
of camptothecin or topotecan. In fact, with both compounds,
the viability of RB-transfected Saos-2 cells decreased much
more slowly than that of the parental cells. As shown in
Fig. 1B, after 72 h of treatment with 100 nM camptothecin,
cell viability decreased by only 10% in RB-transfected clones,
while the reduction was about 70% in parental cells. Accord-
ingly, also the frequency of apoptotic cells was much less
(8.1%) in RB-transfected clones than in parental cells
(64.2%) (Table 1), suggesting a suppressive in£uence of pRb
on the apoptotic pathway. Furthermore, the e¡ects of camp-
tothecin on JNK activation and on c-Jun phosphorylation
were also much lower in RB-transfected than in parental cells.
For example, the treatment with 100 nM camptothecin over
48 h increased the extent of phosphorylated c-Jun by only
20% in transfected cells, in comparison with an eightfold in-
crease in parental cells (Fig. 5).
4. Discussion
The retinoblastoma protein plays an important role in reg-
ulating the progression of the cell cycle in normal mammal
cells [20]. Inactivation or loss of pRb impedes cell cycle exit
and induces deregulation in DNA proliferation, favoring tu-
morigenesis in a number of cases [21^23].
We have undertaken research on the mechanisms which
induce apoptosis in tumor cells defective in pRb function
and we have documented that human retinoblastoma Y79
cells, which lack pRb and express functional p53, are suscep-
tible to apoptosis after treatment with several compounds [24^
27]. Particular e¡ectiveness was observed using camptothecin
or its analogue topotecan, which behave as inhibitors of top-
oisomerase I by stabilizing enzyme^DNA cleavable complexes
[28]. Their apoptotic e¡ect seems to be correlated with a re-
markable increase in p53 level which is most likely a conse-
quence of the conversion of p53 from a latent form into an
active one [24].
This paper describes the cytotoxic e¡ect determined by the
inhibitors of topoisomerases on human osteosarcoma Saos-2
cells, which contain a non-functional form of pRb. The results
indicate that camptothecin was the most active compound
among the di¡erent inhibitors tested, although its e⁄cacy in
Saos-2 cells was lower than in retinoblastoma Y79 cells [24].
The camptothecin e¡ect on the viability of Saos-2 cells was a
consequence of the induction of apoptosis, as evidenced by
light and £uorescent microscopy and £ow cytometry. Because
Saos-2 cells are lacking in p53, our ¢nding indicates that ap-
optosis can occur in Rb-de¢cient cells also by p53-independ-
ent pathways. The apoptotic e¡ect was accompanied in Saos-2
cells by an increase both in the activity of JNK/SAPK and in
the extent of phosphorylation of c-Jun, a transcriptional fac-
tor which is phosphorylated by JNK at Ser63 and Ser73 with-
in its N-terminal transactivation domain [29]. In addition,
camptothecin induced the activation of caspases, the proteases
involved in the execution phase of apoptosis [17]. Our results
suggest that the activation of JNK precedes the activation of
Fig. 5. The activation of JNK induced by camptothecin in Saos-2
cells. Parental and RB-transfected cells were cultured for 48 h with
or without 100 nM camptothecin. 100 WM z-VAD was added as
reported in the ¢gure. At the end cell lysates were prepared and
employed to estimate the activity of JNK (A), using a GST c-Jun
fusion protein as described in Section 2, or the extent of
phosphorylated c-Jun (B). Western blotting analysis was performed
using a speci¢c antibody which recognizes phosphorylated c-Jun.
The levels of activated JNK and phosphorylated c-Jun were esti-
mated by means of densitometric analysis (C).
Fig. 6. Expression of pRb in RB-transfected Saos-2 cells. Protein
extracts (about 50 Wg) were prepared either from parental (lane 1)
or RB-transfected (lane 2) Saos-2 cells and analyzed by Western
blotting for pRb expression. Proteins were resolved in SDS^7.5%
polyacrylamide gel and proteins were immunoblotted and detected
using a speci¢c antibody. Only clone C25 is shown, all other trans-
fectants showed similar expression of pRb.
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caspases, because z-VAD, a general inhibitor of caspases, did
not modify the e¡ect of camptothecin on c-Jun phosphoryla-
tion.
JNK, a member of the MAP kinase family, seems to exert a
central role in the induction of apoptosis in Saos-2 cells by
either camptothecin or MG132. The activation of JNK is
mediated by dual phosphorylation on speci¢c Thr and Tyr
residues, catalyzed by two MAP kinase kinases, MKK4 and
MKK7 [30]. Numerous protein kinases (such as MEKK1,
MEKK4, ASK1 and MLK3) function as MAP kinase kinase
kinases in the JNK pathway, phosphorylating MKK4 and
MKK7 [30].
It is well known that JNK can be activated in response to
environmental oxidative stress [31]. Studies recently per-
formed by us have demonstrated that treatment of Saos-2
cells with MG132, an inhibitor of the 26S proteasome, en-
hanced JNK activity as well as the level of phosphorylated
c-Jun, although to a lesser extent than camptothecin did. In
the case of MG132, our results show that the activation of
JNK may be considered a consequence of the induction of
oxidative stress (submitted). Instead, camptothecin-induced
apoptosis seems to be independent of oxidative stress. This
conclusion is based on the following: (i) treatment with camp-
tothecin did not modify the endogenous GSH content; (ii)
only a modest increase in the production of H2O2 was ob-
served after the addition of the drug; (iii) the e¡ect of camp-
tothecin was counteracted neither by the addition of exoge-
nous catalase nor by GSH; and ¢nally (iv) the camptothecin
e¡ect was not increased by BSO, an inhibitor of GSH syn-
thesis. Thus it seems that the increasing e¡ect on JNK level
induced by camptothecin is not correlated with oxidative
stress.
However, many authors have provided evidence that the
activation of JNK can be determined by DNA-damaging
agents, such as alkylating agents (mitomycin and cisplatin),
ionizing radiation and adriamycin, without the induction of
oxidative stress [18,19]. Even camptothecin and etoposide,
which are inhibitors of topoisomerase I and II respectively,
have been shown to stimulate both apoptosis and the activity
of JNK [31]. The mechanism by which genotoxic agents in-
duce activation of JNK is unknown at the moment. However,
Kharbanda et al. [32], studying etoposide-induced apoptosis,
have demonstrated that the activation of JNK is correlated
with the activation of MEK kinase I, the ¢rst enzyme in the
JNK pathway.
Although the involvement of JNK in apoptosis has been
clearly established, the mechanism of its apoptotic action is
not currently well understood. c-Jun represents the primary
target of JNK. The phosphorylation of c-Jun leads to the
activation of the transcription factor AP-1. However, a role
of AP-1 in the expression of genes which are involved in ap-
optosis has not yet been described. A possible relationship
between JNK and apoptosis is suggested by the observation
that the anti-apoptotic factor Bcl-2 is a target of JNK and
that as a response to DNA damage JNK may translocate into
the mitochondria, thereby inducing the phosphorylation and
the inactivation of Bcl-2 [33].
This paper compares the e¡ects exerted by the genotoxic
drug camptothecin on parental Saos-2 cells and on stable
clones of RB-transfected cells. We demonstrate that the intro-
duction of RB renders Saos-2 cells not susceptible to the ap-
optotic action of camptothecin. This ¢nding represents the
¢rst proof of the anti-apoptotic action exerted by pRb in
tumor cells against genotoxic drugs.
Recently Shim et al. [34] observed that apoptotic cell death
induced by ultraviolet radiation is abrogated in HEK293 cells
transiently transfected with a plasmid expressing pRb. This
fact has been interpreted as a result of the interaction of
pRb with JNK and the consequent inhibition of the intra-
cellular signal induced by JNK. In line with this ¢nding our
paper provides evidence that the introduction of pRb sup-
presses the e¡ect induced by camptothecin both on the activ-
ity of JNK and on the phosphorylation of c-Jun. Therefore, it
seems that pRb can exert a general anti-apoptotic e¡ect
through the control of the activity of JNK. Consequently,
tumor cells which are lacking in pRb seem to be particularly
susceptible to undergoing cell death when exposed to apopto-
tic inducers.
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